General Info

GTC Biotherapeutics develops, produces and markets therapeutic proteins through transgenic animal technology. The company s lead product is ATryn, a recombinant form of human antithrombin. The company also focuses on developing a recombinant human serum albumin, a malaria vaccine, and a CD137 antibody to solid tumors. The company enters into partnering arrangements, or external programs, in which its technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics and products that are difficult to produce in significant quantities from conventional recombinant production systems. The company s external program collaborations are focused on developing transgenic versions of products that include monoclonal antibodies and immunoglobulin fusion proteins for conditions such as rheumatoid arthritis, HIV/AIDS and cancer. GTC Biotherapeutics is headquartered in Framingham, Mass.